Castration-resistant Prostate Cancer
100
17
26
39
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
17 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.0%
16 terminated out of 100 trials
70.9%
-15.6% vs benchmark
4%
4 trials in Phase 3/4
44%
17 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 39 completed trials
Clinical Trials (100)
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Bipolar Androgen Therapy + Carboplatin in mCRPC
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Testosterone Therapy in Castration Resistant Prostate Cancer
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway